The drug is manufactured by Novo Nordisk and administered as a weekly injection under the skin using a prefilled, single-dose pen
Slowing gastric emptying and reducing appetite Decreasing postprandial and fasting glucose, as well as serum triglycerides Pharmacokinetics Synthetic GLP-1 agonists are resistant to degradation by DPP-4 , giving them a longer half-life than endogenous GLP-1
It has a minimal impact on protein quality and mineral content, though it may reduce certain B vitamins 9 and cause minor flavor changes 10
They are patent-protected branded products, and manufacturers set list price around research recovery, market position, and expected payer mix
Expect to see this available in the later part of 2021
That is why every step - from manufacturing to packaging to testing - happens right here in the USA